![Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e1baff69-5b5a-4f27-b790-71f244e1f4b9/gr1_lrg.jpg)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology
![Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Semantic Scholar Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8608bbb23bb7e27ec775286d0e6edd4ffa92251b/4-Table1-1.png)
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Semantic Scholar
![Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing) DOI:10.1039/C8MD00198G Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing) DOI:10.1039/C8MD00198G](https://pubs.rsc.org/image/article/2018/MD/c8md00198g/c8md00198g-f15_hi-res.gif)
Targeting Brd4 for cancer therapy: inhibitors and degraders - MedChemComm (RSC Publishing) DOI:10.1039/C8MD00198G
![Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer: Trends in Pharmacological Sciences Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer: Trends in Pharmacological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/11a105c7-2596-49f1-860d-16e90f6d3b1d/gr1_lrg.jpg)
Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer: Trends in Pharmacological Sciences
![Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/646c6653-d330-47d4-bf64-7a0751380e55/figs1.jpg)
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
![Frontiers | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases | Pharmacology Frontiers | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases | Pharmacology](https://www.frontiersin.org/files/Articles/474358/fphar-10-01315-HTML-r1/image_m/fphar-10-01315-g002.jpg)
Frontiers | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases | Pharmacology
![Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41389-021-00316-z/MediaObjects/41389_2021_316_Fig1_HTML.png)
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis
![Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors | Journal of Clinical Oncology Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2018/jco.2018.36.issue-30/jco.2018.78.2292/20181004/images/large/jco.2018.78.2292t3.jpeg)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors | Journal of Clinical Oncology
![Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma - ScienceDirect Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S221138352030633X-fx1.jpg)